cresence AS

A new approach to neurodegeneration

Cresence AS is a limited company founded in 2020 by a team of researchers and drugs development experts.
We focus on research and development of innovative technologies and breakthrough therapies for unmet medical needs and orphan diseases.

our model

we research

We find molecules with solid scientific data as new therapeutic opportunities.​

we develop

Through a development plan we add value to molecules to become new neuroprotective drugs.

we maximize

After significant scientific evidence we maximize the efficiency of the orphan drugs for niche indications.

we optimize

To provide a rapid return on investment we optimize and complete the drug development.

Biotech Cresence AS

a new biotech for neurological disorders

The development of the lead products CRES101 ans CRES102 for the treatments of neurodegenerative diseases strengthens the offert of innovative therapeutic solutions.

About us

We are an agile corporate structure of Directors and Scientific Advisors.
Our commitment is to turn our efforts into research, with passion, competence and boldness.

Anders Fugelli Cresence AS

Dr. anders fugelli

Co-founder and Chairman

Francois Curtin Cresence AS

Dr. francois curtin

Co-founder and Vice Chairman

Alois Berger Cresence AS

Prof. alois b. lang

Co-founder and Member

Ferdinando Nicoletti Cresense AS

Prof. Ferdinando Nicoletti

Co-founder and Advisor

Giuseppe Scalabrino Cresence AS

Prof. Giuseppe Scalabrino

Senior Advisor

Our Journal

Working closely with our partnered centres and universities, we contribute to the progress of Life Sciences knowledge.